Free tool
FAERS Monitor: Isolyte P In Dextrose 5% In Plastic Container
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019873 or its brand name (Isolyte P In Dextrose 5% In Plastic Container, Dextrose, Magnesium Chloride, Potassium Chloride, Potassium Phosphate, Dibasic, Sodium Acetate). Reports on generic versions are filed under their own applications.
Reports
7
Serious
7
100% of reports
Hospitalization
4
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- alanine aminotransferase increased2
- aspartate aminotransferase increased2
- blood bilirubin increased2
- drug abuse2
- gamma-glutamyltransferase increased2
- neuroleptic malignant syndrome2
- off label use2
- anaemia1
- asthenia1
- autoimmune hepatitis1
- cardiac failure1
- death1
- drug ineffective1
- escherichia urinary tract infection1
- hyperthermia malignant1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2016 | 2 |
| 2020 | 1 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,152 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperthermia malignant | 1 | 2021.3 | 329.0 | 504 |
| escherichia urinary tract infection | 1 | 707.0 | 115.1 | 176 |
| neuroleptic malignant syndrome | 2 | 506.8 | 157.1 | 567 |
| autoimmune hepatitis | 1 | 432.1 | 70.4 | 107 |
| gamma-glutamyltransferase increased | 2 | 271.2 | 84.1 | 302 |
| blood bilirubin increased | 2 | 222.5 | 69.0 | 248 |
| aspartate aminotransferase increased | 2 | 113.1 | 35.1 | 125 |
| alanine aminotransferase increased | 2 | 97.9 | 30.3 | 107 |
| drug abuse | 2 | 72.2 | 22.4 | 79 |
| cardiac failure | 1 | 37.4 | 6.1 | 8 |
| anaemia | 1 | 15.8 | 2.6 | 3 |
| asthenia | 1 | 8.0 | 1.3 | 1 |
| off label use | 2 | 6.9 | 2.1 | 5 |
| death | 1 | 3.5 | 0.6 | 0 |
| drug ineffective | 1 | 2.3 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.